Concepedia

Author

Kenneth Down

GlaxoSmithKline (United Kingdom)ORCID

Also Known As

K. Down, K.D. Down, Kenneth D. Down, Kenneth Down

14

Publications

453

Citations

7

H-Index

28

Concepts

All Affiliations

GlaxoSmithKline (United Kingdom)Age UKMolecular Discovery (United Kingdom)
KD

About

Kenneth Down is an author at GlaxoSmithKline (United Kingdom) specializing in drug discovery, natural sciences, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

201

2

Natural Sciences

5

5

201

3

Biochemistry

4

4

189

4

Allergy

1

1

130

5

Biomolecular Engineering

1

1

12

Kenneth Down

×

6

Publications

435

Citations

6

H-Index

YearCitations

Investigation of a Bicyclo[1.1.1]pentane as a Phenyl Replacement within an LpPLA <sub>2</sub> Inhibitor

Nicholas D. Measom, Kenneth Down, David J. Hirst,

ACS Medicinal Chemistry Letters

2016

234

Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease

Kenneth Down, Augustin Amour, Ian T. Baldwin,

Journal of Medicinal Chemistry

2015

130

Discovery of 6-Aryl-7-alkoxyisoquinoline Inhibitors of IκB Kinase-β (IKK-β)

J.A. Christopher, Paul Bamborough, Catherine M. Alder,

Journal of Medicinal Chemistry

2009

30

Optimization of Orally Bioavailable PI3Kδ Inhibitors and Identification of Vps34 as a Key Selectivity Target

Z.A. Henley, Augustin Amour, Nick Barton,

Journal of Medicinal Chemistry

2019

18

Discovery of Potent, Efficient, and Selective Inhibitors of Phosphoinositide 3-Kinase δ through a Deconstruction and Regrowth Approach

Nick Barton, M.A. Convery, Anthony W. J. Cooper,

Journal of Medicinal Chemistry

2018

12

The discovery and initial optimisation of pyrrole-2-carboxamides as inhibitors of p38α MAP kinase

Kenneth Down, Paul Bamborough, Catherine M. Alder,

Bioorganic & Medicinal Chemistry Letters

2010

11

Page 1